1. Home
  2. BNR vs CRBP Comparison

BNR vs CRBP Comparison

Compare BNR & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

HOLD

Current Price

$15.00

Market Cap

179.7M

Sector

Health Care

ML Signal

HOLD

Logo Corbus Pharmaceuticals Holdings Inc.

CRBP

Corbus Pharmaceuticals Holdings Inc.

HOLD

Current Price

$11.77

Market Cap

184.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNR
CRBP
Founded
2014
2009
Country
China
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
179.7M
184.4M
IPO Year
2019
2014

Fundamental Metrics

Financial Performance
Metric
BNR
CRBP
Price
$15.00
$11.77
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$45.50
AVG Volume (30 Days)
12.6K
301.6K
Earning Date
06-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$4,822,272.00
Revenue This Year
$111.65
N/A
Revenue Next Year
N/A
$116.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
97.62
52 Week Low
$2.80
$6.73
52 Week High
$41.72
$20.56

Technical Indicators

Market Signals
Indicator
BNR
CRBP
Relative Strength Index (RSI) 34.47 59.27
Support Level $7.99 $9.32
Resistance Level $22.50 $12.41
Average True Range (ATR) 0.88 0.94
MACD -0.10 -0.03
Stochastic Oscillator 1.67 68.85

Price Performance

Historical Comparison
BNR
CRBP

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Share on Social Networks: